Saturday, September 5

Browsing: technologyassisted

Research

Multicenter evaluation of anatomical landmark versus technology-assisted techniques for chemotherapy venous access device implantation

By NewsCancerSeptember 1, 20260

Patient recruitment and general considerationsThis study recruited patients with various types of primary cancer, with the largest case series consisting…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1

Managing High-Risk BCLC-C HCC in a Younger Fit Patient

CELMoD Potency and Cereblon-Mediated Activity in Multiple Myeloma

Browsing: technologyassisted

Multicenter evaluation of anatomical landmark versus technology-assisted techniques for chemotherapy venous access device implantation

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1

Managing High-Risk BCLC-C HCC in a Younger Fit Patient

CELMoD Potency and Cereblon-Mediated Activity in Multiple Myeloma

<![CDATA[Conclusions and Award Ceremony]]>

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1

Managing High-Risk BCLC-C HCC in a Younger Fit Patient

CELMoD Potency and Cereblon-Mediated Activity in Multiple Myeloma

<![CDATA[Conclusions and Award Ceremony]]>

Latest Post

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1

Managing High-Risk BCLC-C HCC in a Younger Fit Patient

CELMoD Potency and Cereblon-Mediated Activity in Multiple Myeloma

Subscribe to Updates

What's Hot

Browsing: technologyassisted